<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78778E97-5A2E-40A6-A88F-137A343A3530"><gtr:id>78778E97-5A2E-40A6-A88F-137A343A3530</gtr:id><gtr:name>University of Toronto</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F31D4A66-92AA-4002-BD5A-B0E539ACF08F"><gtr:id>F31D4A66-92AA-4002-BD5A-B0E539ACF08F</gtr:id><gtr:name>Mount Sinai Hospital (USA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E68501E9-4C3B-4A78-B85D-88EF2B577390"><gtr:id>E68501E9-4C3B-4A78-B85D-88EF2B577390</gtr:id><gtr:name>University of California, San Francisco</gtr:name><gtr:address><gtr:line1>50 Beale Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78778E97-5A2E-40A6-A88F-137A343A3530"><gtr:id>78778E97-5A2E-40A6-A88F-137A343A3530</gtr:id><gtr:name>University of Toronto</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F31D4A66-92AA-4002-BD5A-B0E539ACF08F"><gtr:id>F31D4A66-92AA-4002-BD5A-B0E539ACF08F</gtr:id><gtr:name>Mount Sinai Hospital (USA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E68501E9-4C3B-4A78-B85D-88EF2B577390"><gtr:id>E68501E9-4C3B-4A78-B85D-88EF2B577390</gtr:id><gtr:name>University of California, San Francisco</gtr:name><gtr:address><gtr:line1>50 Beale Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/127B4969-E896-407E-BB05-C58E1E469E55"><gtr:id>127B4969-E896-407E-BB05-C58E1E469E55</gtr:id><gtr:firstName>Tom</gtr:firstName><gtr:surname>Milne</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12009%2F6"><gtr:id>187C2C8B-07AD-4D69-93D2-15E5FD46BDFF</gtr:id><gtr:title>The Epigenetic Control of Gene Expression in Leukaemia and Haematopoiesis</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12009/6</gtr:grantReference><gtr:abstractText>There are many specialized cells in our body designed to carry out different specific tasks, and yet they all contain the same genetic information. During development, cells receive information that they translate into specific developmental outputs, usually without altering their DNA sequence. Changes in cell phenotype that do not alter the DNA sequence are referred to as ?epigenetic?. Human diseases such as cancer often result from changes in gene expression patterns that are not always associated with DNA mutations, thus epigenetic changes are also a key mechanism in human disease. In living cells, genes do not exist as ?naked? DNA, but as a highly conserved protein/DNA complex termed chromatin. The basic subunit of chromatin is the nucleosome, which consists of DNA wrapped around an octamer core of globular histone proteins, two each of H2A, H2B, H3, and H4.The N terminal &amp;quot;tails&amp;quot; of these histone proteins are chemically modified with &amp;quot;marks&amp;quot; such as methylation or acetylation. The specific carriers of epigenetic information have not been completely worked out, but emerging work over the past decade has suggested that epigenetic information is established in part by the modification of histone tails. We are specifically interested in how changes in histone methylation lead to transcriptional misregulation in human disease. As a system for asking specific questions about this very complex problem, I work on the Mixed Lineage Leukemia 1 (MLL1) protein, a histone methyltransferase that controls gene activation during development. Mutations in MLL1 also cause aggressive leukaemias in both children and adults. Specific information about MLL1 activity will not only provide potential therapeutic information for this subset of human leukemias, but will also have broader implications for stem cell development and the epigenetic regulation of gene expression in other human diseases.</gtr:abstractText><gtr:technicalSummary>The Mixed Lineage Leukaemia 1 protein (MLL1) protein is important for the epigenetic regulation of gene expression during stem and progenitor cell development but is also mutated in a subset of aggressive human leukaemias. The most common leukaemic disruptions of the MLL1 gene are chromosome translocations that fuse the N terminus of MLL1 in frame with over 40 different partner genes creating novel fusion proteins. Recent work has suggested that wild type MLL1 and MLL1 fusion proteins cooperate in leukaemogenesis by together causing aberrant epigenetic profiles at target genes in vivo. Epigenetic changes are often defined as heritable changes in gene expression or chromosome stability that don?t alter the underlying DNA sequence. We are interested in identifying the key molecular events in MLL1 mediated leukaemogenesis in order to fully understand the epigenetic basis for this disease. This major goal has been divided into three key questions: 1) What key downstream gene targets are essential for MLL1 mediated leukaemogenesis?; 2) how do MLL1 and MLL1 fusion proteins control epigenetic gene regulation on a molecular level?; and 3) how are MLL1 and MLL1 fusion proteins recruited to important gene targets in the cell? To answer these questions, we are using xenograft transplant assays to identify Leukaemic Stem Cells (LSCs) in MLL1 patient samples, ChIP-seq to identify and characterise direct gene targets in specific haematopoietic cell populations, small molecular inhibitors and siRNA combined with ChIP and ChIP-seq to determine how MLL1 fusion proteins regulate gene targets in the cell and MLL1 domain analysis coupled with genome wide techniques to determine how MLL1 is recruited to gene targets in the cell. Answering these questions may not only be useful for future therapeutic strategies, but will also inform our basic understanding of epigenetic gene regulation during normal stem and progenitor cell development.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2224000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Northern Institute for Cancer Research Newcastle</gtr:department><gtr:description>Epigenetic inhibitors in MLL-AF4 leukaemias I</gtr:description><gtr:id>9ACBECBF-6AD2-4F99-AF96-2DC4D5B467B9</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545a82ef8b9177.64080505-1</gtr:outcomeId><gtr:partnerContribution>Dr Jian JIn's lab at Mount Sinai in the US are synthesizing large amounts of compounds for preclinical work and molecular analysis.

The Newcastle lab of Prof Olaf Heidenreich are conducting xenograft transplant analysis of leukaemias and the effect of specific inhibitors that control the activity of a class of epigenetic repressor proteins termed the PRC complex. These novel inhibitors are also being tested in combination with Dexamethasome, a commonly used chemotherapeutic agent.</gtr:partnerContribution><gtr:piContribution>We are providing ChIPseq and bioinformatic analysis of leukaemia cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>microRNA repression of cancer cells</gtr:description><gtr:id>02F2626A-4167-426A-9284-260F6F405BE1</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545a820d377ff4.91011639-1</gtr:outcomeId><gtr:partnerContribution>The lab of Dr. Tudor Fulga at the WIMM is providing expertise and tools for analyzing micro RNAs.</gtr:partnerContribution><gtr:piContribution>We are providing cell lines and expertise on the mechanisms of leukaemia. In collaboration with Dr. Tudor Fulga, we are together directing a project that explores the role of micro RNAS in poor prognosis human leukaemia with an eventual hope this could be of therapeutic use.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>M. D. Anderson Cancer Center</gtr:department><gtr:description>BCL-2 and epigenetic inhibitors in MLL-AF4 leukaemias</gtr:description><gtr:id>C91AA4F0-26CD-4BCF-A49F-AA6EC17ED0B4</gtr:id><gtr:impact>This collaboration has resulted in the publication of a paper in Cell Reports in 2015: Benito et al ... Milne TA,
Konopleva M. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
Cell Rep. 2015 Dec 29;13(12):2715-27. doi: 10.1016/j.celrep.2015.12.003. PubMed PMID: 26711339;</gtr:impact><gtr:outcomeId>567815cb2f35b8.81402305-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators at MD Anderson in Texas were able to use a newly developed drug to BCL-2 to show that this drug could stop leukemia growth in model systems. This provides a rationale for moving forward with this drug in clinical trials. Further, using our molecualr analysis as a foundation, they have started testing the effect of BCL-2 inhibitors in combination with other epigenetic drugs.</gtr:partnerContribution><gtr:piContribution>t(4;11) translocations preoduce rare but highly aggressive leukemias in infants, children and adults. We performed an extensive molecular analysis that showed that this mutation directly results in the upregulation of a gene target named BCL-2 that results in a suppression of apoptosis. Our molecular analysis also provided a rationale for using different specific drug combinations to0 combat these leukemias.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Radcliffe Department of Medicine</gtr:department><gtr:description>Developing a model of Infant MLL-AF4 leukemia</gtr:description><gtr:id>F58D9780-8AF7-4FFC-87C2-D70E8A50D274</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>56e138e4936f74.25187092-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators are providing expertise on human B cell development and on targeting the correct cell type to produce a model for this aggressive infant leukaemia.</gtr:partnerContribution><gtr:piContribution>We are collaborating with the labs of Dr. Irene Roberts and Dr. Anindita Roy. We are providing help and expertise on designing contructs to express the MLL-AF4 infant leukaemia protein</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Structural Genomics Consortium (SGC)</gtr:department><gtr:description>Inhibition of epigenetic proteins in leukemia</gtr:description><gtr:id>02E05F04-2124-45EC-84F2-752E537060BE</gtr:id><gtr:impact>None yet, but we expect to publish some papers soon.</gtr:impact><gtr:outcomeId>ihbRQJgtT7y-2</gtr:outcomeId><gtr:partnerContribution>The SGC at the University of Toronto has provided several high quality inhibitors for methyltransferases and demethylases.The SGC at the University of Oxford has provided several high quality inhibitors for bromodomain containing proteins</gtr:partnerContribution><gtr:piContribution>Testing inhibitors for their effect on leukemic cell growth</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Toronto</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Strcutural Genomics Consortium</gtr:department><gtr:description>Inhibition of epigenetic proteins in leukemia</gtr:description><gtr:id>55E925CE-4C66-4ADD-84D3-C4AB6BF7A417</gtr:id><gtr:impact>None yet, but we expect to publish some papers soon.</gtr:impact><gtr:outcomeId>ihbRQJgtT7y-1</gtr:outcomeId><gtr:partnerContribution>The SGC at the University of Toronto has provided several high quality inhibitors for methyltransferases and demethylases.The SGC at the University of Oxford has provided several high quality inhibitors for bromodomain containing proteins</gtr:partnerContribution><gtr:piContribution>Testing inhibitors for their effect on leukemic cell growth</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mount Sinai Hospital (USA)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Epigenetic inhibitors in MLL-AF4 leukaemias I</gtr:description><gtr:id>FDAAE3CF-6897-4913-8F24-A14BBDC86980</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545a82ef8b9177.64080505-2</gtr:outcomeId><gtr:partnerContribution>Dr Jian JIn's lab at Mount Sinai in the US are synthesizing large amounts of compounds for preclinical work and molecular analysis.

The Newcastle lab of Prof Olaf Heidenreich are conducting xenograft transplant analysis of leukaemias and the effect of specific inhibitors that control the activity of a class of epigenetic repressor proteins termed the PRC complex. These novel inhibitors are also being tested in combination with Dexamethasome, a commonly used chemotherapeutic agent.</gtr:partnerContribution><gtr:piContribution>We are providing ChIPseq and bioinformatic analysis of leukaemia cells</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Radcliffe Department of Medicine</gtr:department><gtr:description>The role of RUNX2 in MLL-AF9 acute myeloid leukaemia</gtr:description><gtr:id>FC4F96CB-4D89-40E9-88F5-FB3938B5134F</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:outcomeId>YjfhtBzzD6Z-1</gtr:outcomeId><gtr:partnerContribution>Prof Paresh Vyas and I are jointly supervising a student and directing the goals of the project.</gtr:partnerContribution><gtr:piContribution>We are analyzing the role of RUNX2 in acute myeloid leukaemias.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SMYD2 inhibitors in leukaemias</gtr:description><gtr:id>9DBE0A9F-3E5E-46C2-A572-12D26D49F1DE</gtr:id><gtr:impact>None yet.</gtr:impact><gtr:outcomeId>Ksr4Y8MC1Cc-1</gtr:outcomeId><gtr:partnerContribution>Astra Zeneca have provided large quantities of a novel and specific compound that inhibits the activity of the SMYD2 methyltransferase.</gtr:partnerContribution><gtr:piContribution>We are testing SMYD2 inhibitors on the growth of leukaemia cells and trying to understand the molecular mechanisms underlying SMYD2 function.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Francisco</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine (UCSF)</gtr:department><gtr:description>ChIP sequencing in acute leukemias</gtr:description><gtr:id>B5B341A3-6647-4164-836A-5B95319FC739</gtr:id><gtr:impact>This work has resulted in the publication of several papers:

1: Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L,
Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger
SM, Lazarus H, Tallman MS, Rowe JM, Litzow MR, Guzman ML, Allis CD, Roeder RG,
M&amp;uuml;schen M, Paietta E, Elemento O, Melnick AM. Integrative epigenomic analysis
identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic
leukemia. Cancer Discov. 2012 Nov;2(11):1004-23. doi:
10.1158/2159-8290.CD-12-0208. Epub 2012 Oct 29. PubMed PMID: 23107779;

2: Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, Biswas D, Roeder 
RG, Allis CD, Melnick A, de Bruijn MF, Milne TA. RUNX1 is a key target in t(4;11)
leukemias that contributes to gene activation through an AF4-MLL complex
interaction. Cell Rep. 2013 Jan 31;3(1):116-27. doi:
10.1016/j.celrep.2012.12.016. Epub 2013 Jan 24. PubMed PMID: 23352661;

3: Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA,
Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, Park E, 
Huang C, Nahar R, Kweon SM, Shojaee S, Chan LN, Yu J, Kornblau SM, Bijl JJ, Ye
BH, Ansel KM, Paietta E, Melnick A, Hunger SP, Kurre P, Tyner JW, Loh ML, Roeder 
RG, Druker BJ, Burger JA, Milne TA, Chang BH, M&amp;uuml;schen M. Self-enforcing feedback 
activation between BCL6 and pre-B cell receptor signaling defines a distinct
subtype of acute lymphoblastic leukemia. Cancer Cell. 2015 Mar 9;27(3):409-25.
doi: 10.1016/j.ccell.2015.02.003. PubMed PMID: 25759025;</gtr:impact><gtr:outcomeId>igNo6eKUMJR-1</gtr:outcomeId><gtr:partnerContribution>Dr. Huimin Geng performed bioinformatics analysis of ChIPseq data, Dr. Markus Muschen's lab provided patient samples and performed pre clinical studies on acute leukaemias</gtr:partnerContribution><gtr:piContribution>Providing ChIP sequencing datasets in patient samples for BCL6, E2A-PBX and MLL-AF4.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Radcliffe Department of Medicine</gtr:department><gtr:description>RUNX1 in leukemia</gtr:description><gtr:id>0DA8E73A-6F4D-4A90-9C99-646F78303DD8</gtr:id><gtr:impact>We have published a 2013 paper together in the the journal Cell Reports:

Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, Biswas D, Roeder 
RG, Allis CD, Melnick A, de Bruijn MF, Milne TA. RUNX1 is a key target in t(4;11)
leukemias that contributes to gene activation through an AF4-MLL complex
interaction. Cell Rep. 2013 Jan 31;3(1):116-27. 
PubMed PMID: 23352661</gtr:impact><gtr:outcomeId>WccsC13svLF-1</gtr:outcomeId><gtr:partnerContribution>The lab of Dr. Marella De Bruijn has provided us with reagents and expert advice.</gtr:partnerContribution><gtr:piContribution>We initiated an analysis on the role of RUNX1 in MLL leukemias.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Children with Cancer UK 25th anniversary celebration</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>57E8EE2F-0035-4123-A07B-F463D969EA35</gtr:id><gtr:impact>I presented a poster at this event designed as an outreach from the charity Children with Cancer UK to members of parliament and to members of the general public who had contributed to the charity. I mainly talked about my work and the impact of basic research on disease with members of the general public who came to my poster. I also talked to some of the other organisers and guests of the event and I emphasised how their funding has helped my research and how this might one day hopefully impact treating children with leukaemia. I also talked to other scientists at the event about their research.

In this case I think the strongest impact was on my own perspective. I talked to a few different couples who were contributors to the charity and had lost children to leukaemia. These interactions have brought me more focus in my own research.</gtr:impact><gtr:outcomeId>534be30b09ea61.78563562</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>http://www.childrenwithcancer.org.uk/News/celebrating-science-2013</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Epigenetic drug targeting talk at the Royal Berkshire Hospital in Reading</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C230EAE3-AA4A-458A-80B8-10151C60A570</gtr:id><gtr:impact>My talk was geared towards the audience which consisted of consultants, associate specialists and 2 trainee haematology registrars (Oxford rotation) as well as specialist nurses, and clinical trials nurses. The talk was designed to show how basic research in epigenetics could lead to drug design that could eventually be used in the clinic.

The engagement included many individual questions after the talk during the lunch and included interesting comments from clinicians about the potential practicality of different drug designs.</gtr:impact><gtr:outcomeId>566f4f8873a347.85452858</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Oxford International Careers Day</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>5B38554B-6B9B-4C3E-89F6-F4A4F70645CA</gtr:id><gtr:impact>I was a member of an International Academia (Science) panel consisting of myself and three other international scientists, on Jan 25,2014 at the University of Oxford exam schools. We were all asked to talk for about 10 minutes on our experiences to date, how we got into our roles, the opportunities and challenges we have faced, and then we offered tips for students interested in similar / parallel roles and academic careers.

After our brief talks, we fielded several questions from the audience (about 20 people) asking for specific advice on an international career in science (ex moving countries and working in other countries).</gtr:impact><gtr:outcomeId>534bec1baa9ac9.57199252</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.careers.ox.ac.uk/international-careers-day-january-25th-2014/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk in Leuven</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F05A1A77-1591-4A4E-BC58-1E693D467292</gtr:id><gtr:impact>A scientific talk at the Department of Pharmaceutical and Pharmacological Sciences, UZ St. Rafael, Leuven, Belgium that stimulated questions from the audience.

After my talk, we discussed applying for joint funding for an ERC grant.</gtr:impact><gtr:outcomeId>566f5601e5ba63.80335201</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at the Annual Oxford Developmental Biology Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>392AEDF4-F26C-4889-860F-DC5B11A28CB8</gtr:id><gtr:impact>The talk presented a leukaemia perspective to a developmental biology crowd. The talk stimulated several questions and discussions afterwards.

There were discussions with colleagues about the relationship between development and leukaemia.</gtr:impact><gtr:outcomeId>566f5066c88732.63781921</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Career talk to students and postdocs at the Weatherall Institute of Molecular Medicine</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BB23D13D-5666-40FE-B6B3-FBC857E93FB4</gtr:id><gtr:impact>The career talk stimulated much discussion afterwards about careers in science and resulted in the formation of a postdoc association at the WIMM. The postdoc association are engaged in different issues involving postdocs and PhD students and career planning.

After my talk, several postdocs approached me and directly suggested the formation of the postdoc association.</gtr:impact><gtr:outcomeId>566f54feee8a38.04246934</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at ChemBio Hub Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>CF0774B3-BAA4-4EE2-9BC2-845A03F7A44F</gtr:id><gtr:impact>The target audience consisted of members of industry, chemists, drug developers, members of the Structural Genomics Consortium (SGC) and basic researchers. The purpose of the meeting was to bring together people Oxford-wide who were interested in drug development.

Several collaborations were established and contacts between industry and academics were strengthened.</gtr:impact><gtr:outcomeId>568521a007aa29.24275112</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:url>https://chembiohub.ox.ac.uk/symposium2014/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Edinburgh, MRC Centre for Regenerative Medicine talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D51C1C9D-F9D6-47EC-8FD7-568A6C383173</gtr:id><gtr:impact>The talk stimulated many questions and discussion afterwards.

The most important impact was that the talk caused a collaboration to form between my lab and another lab at the institute.</gtr:impact><gtr:outcomeId>566f513aafacb4.36062877</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford chromatin and transcription meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EF7ED8A2-43F5-4F78-9FE6-741FB36195A0</gtr:id><gtr:impact>Talk initiated interactions and discussion with fellow scientists at Oxford across departments that don't normally have any contact.

All the transcription researchers at Oxford became much more aware of each others research thus increasing the possibility for local collaborations.</gtr:impact><gtr:outcomeId>566f4e375d62f4.86036913</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual Molecular Haemopoiesis conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2FA90F7-4054-49E2-A307-6ABA8E0F2A81</gtr:id><gtr:impact>I helped plan and organize the annual Molecular Haemopoiesis conference number 17 (2014) and 18 (2015).

The Molecular Haemopoiesis conference attracts researchers from all over the UK and Europe and also a few from North America. The specific impact it has is that it is an excellent opportunity for researchers to mix and exchange ideas and the meeting is effective at raising the intellectual capital of UK science as well as raising the profile of UK science within the international community. Directly due to these and past Molecualr Haematology meetings I have personally sopken to individual inter</gtr:impact><gtr:outcomeId>566f540c3ce1f0.85047363</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hosted 2 A-Level students for a week long work experience placement</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A6D2BD27-44A4-4634-814A-35C90609C1A4</gtr:id><gtr:impact>Talked and hosted 2 A-Level students for a week long work experience placement</gtr:impact><gtr:outcomeId>58aee74a592d53.08921310</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Summer Internship</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DC87F0F1-0E8E-4A64-BF57-C5179D0AD62D</gtr:id><gtr:impact>An undergraduate student had an internship in the lab for several weeks in the summer in order to learn more about how science works and how research is conducted.

After his internship, the student expressed a strong interest in one day becoming a scientist himself.</gtr:impact><gtr:outcomeId>545b3b33adf395.03660640</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Athena Swan UCL Career Day Event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>62C4F0DF-989D-4C1B-AF58-67A45CFC0275</gtr:id><gtr:impact>The target audience consisted of about 30-50 early career scientists, graduate students and postgraduates on April 10th, 2014. I was the first of 6 speakers for a UCL Cancer Institute Athena Swan Week Career Talks Day. I mainly gave a talk on my own career path and I included advice and hints on how to make career choices in science. I also gave practical advice on several different areas such as how to build a competitive CV, looking for and applying for jobs, preparing for an interview and presenting a job talk.

The engagement included many individual questions after the talk during the lunch and coffee breaks covering a wide range of topics including work/life balance, applying for jobs in academia as well as applying for jobs in industry. I also received several follow up emails from people asking for specific advice about CV's and interviews.</gtr:impact><gtr:outcomeId>534be685d84ea8.57177672</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.ucl.ac.uk/cancer/athenaswan/swanci</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>48104</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grants for research into childhood cancer</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>Children with Cancer UK</gtr:fundingOrg><gtr:id>A47C3B99-1090-436C-A213-C4F16DFB7A3B</gtr:id><gtr:outcomeId>566f0a75aee729.97348262</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Participated in scoping meeting on MRC basic research careers Sept 25, 2013</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BC0B3001-BCBD-4B71-BFC2-03C52C63FC84</gtr:id><gtr:impact>In the interest of nurturing basic research careers to produce the next generation of world class researchers, the MRC Training and Careers Group and the MRC Human Resources team initiated a scoping meeting to discuss the basic research career structures in the MRC. I was part of the scoping meeting and the advice from the subgroup was collated and summarized and distributed to the scoping meeting members. This information provided some initial guidance for the review process that eventually resulted in publication of the document &amp;quot;An MRC review of Next Destinations&amp;quot; and the removal of time-after-the-PhD limits from MRC fellowship applications.</gtr:impact><gtr:outcomeId>566f13b40fa977.00576224</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>https://www.mrc.ac.uk/news/browse/signposting-medical-research-career-options/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>It is a collection of different types of epigenomic data (such as ChIP-seq, RNA-seq, ATAC-seq) that have been made publicly available for other researchers to access.</gtr:description><gtr:id>3C648BCD-6AD1-49B3-A02C-DB98DD332AEF</gtr:id><gtr:impact>Generation of these datasets helped publish a paper (see DOI below) that can be used to help predict useful drug combinations for a subset of aggressive leukaemias. In addition, these datasets are available for other scientists to aid in their research.</gtr:impact><gtr:outcomeId>58a6c3dee865a5.94641324</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Epigenetic ChIP sequencing in normal and patient leukemia cells</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83671</gtr:url><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>We've provided an extensive ChIP-sequencing dataset in a publicly available repository (the Gene Expression Omnibus, GEO) that includes multiple transcription factors in a t(4;11) leukaemia cell line.</gtr:description><gtr:id>CBE0911A-BF63-4458-9553-A07D11ABE0E5</gtr:id><gtr:impact>The generation of this dataset allowed us to find a unique correlation between the RUNX1 transcription factor and a specific set of epigenetic marks in a subset of aggressive childhood leukaemias. This led to the publication of a paper in Cell Reports in 2013. In addition, the datset is freely available to the field and will aid in genomic analysis performed by other labs that are interested in epigenetics and leukaemia.</gtr:impact><gtr:outcomeId>5674073ec90a92.45401113</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Transcription factor ChIP sequencing dataset in the RS4;11 t(4;11) leukaemia cell line</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE42075</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>We performed a novel technique termed Capture C in leukaemia cells to help identify enhancer-promoter interactions at important oncogenes.</gtr:description><gtr:id>00EF54DB-2171-4F32-9FB6-9B4C3EBF3B4E</gtr:id><gtr:impact>We provided a publicly available dataset through GEO that can aid in research by other scientists. In addition, the work generated by this dataset led to an open access publication (see DOI).</gtr:impact><gtr:outcomeId>58a6c51e31f2c3.64262918</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Capture C in t(4;11) leukaemia cells</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE85988</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>We've provided an extensive ChIP-sequencing dataset in a publicly available repository (the Gene Expression Omnibus, GEO) that includes multiple epigenetic marks and chromatin proteins in a t(4;11) leukaemia cell line.</gtr:description><gtr:id>FAC2847D-ADB2-43B1-8DFA-91B53087FA35</gtr:id><gtr:impact>The generation of this dataset has allowed us to predict specific drug combinations, inlcuing the use of a novel epigenetic drug, that might help cure this subset of aggressive childhood leukaemias. In collaboration with another lab at MD Anderson in Texas, this work led to the publication of a paper in 2015 in Cell Reports that showed specific drug combinations can stop the leukaemia from growing. In addition, the datset is freely available to the field and will aid in genomic analysis performed by other labs that are interested in epigenetics and leukaemia.</gtr:impact><gtr:outcomeId>566f0c7ed549e4.39388317</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Epigenetic ChIP sequencing dataset in the SEM t(4;11) leukaemia cell line</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74812</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>ChIP-sequencing for multiple epigenetic proteins and histone marks in an RS4;11 t(4;11) leukaemia cell line.</gtr:description><gtr:id>02CAC8DB-7C03-45A5-8B5D-9D4BF8C7C175</gtr:id><gtr:impact>The generation of this dataset allowed us to find a unique correlation between the RUNX1 transcription factor and a specific set of epigenetic marks in a subset of aggressive childhood leukaemias. This led to the publication of a paper in Cell Reports in 2013. In addition, the datset is freely available to the field and will aid in genomic analysis performed by other labs that are interested in epigenetics and leukaemia.</gtr:impact><gtr:outcomeId>567409092b24c1.36958284</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Epigenetic ChIP sequencing dataset in the RS4;11 t(4;11) leukaemia cell line</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE38403</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>OxStem Oncology</gtr:companyName><gtr:description>There is a pressing need to develop therapeutics which can target stem cells. OxStem Ltd is an investment company (http://www.oxstem.co.uk/, &amp;pound;16.9M invested in the startup) to fund a series of spinouts (&amp;quot;stem companies&amp;quot;) at Oxford. The first such stem company is OxStem Oncology (OSO), a subsidiary company of OxStem Ltd. OxStem Oncology aims to identify a new class of drugs that will differentiate 'cancer stem-like cells' (CSLCs) to more benign states that will improve clinical outcomes and overcome resistance/relapse.</gtr:description><gtr:id>BC967D18-564B-4116-9408-55F908A15A4B</gtr:id><gtr:impact>This spin out has just recently started, but it has attracted investment from the US (via OxStem Ltd) and has generated full time scientific posts for 3 people in the UK so far.</gtr:impact><gtr:outcomeId>57bb12fde02a90.41148436</gtr:outcomeId><gtr:url>http://www.oxstem.co.uk/product-pipeline/oncology</gtr:url><gtr:yearCompanyFormed>2016</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>AFFC9BC9-58E4-465D-A59A-5077716C621D</gtr:id><gtr:title>MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0686fc6871b4d66bec677c0c31347ecd"><gtr:id>0686fc6871b4d66bec677c0c31347ecd</gtr:id><gtr:otherNames>Kerry J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>589462517e77b3.01569074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BEB8027-6FF4-45C0-AF78-46F5873334C4</gtr:id><gtr:title>Mouse models of MLL leukemia: recapitulating the human disease.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a27ff98c559f42e5f2aab1c078749b0"><gtr:id>4a27ff98c559f42e5f2aab1c078749b0</gtr:id><gtr:otherNames>Milne TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a9415414dc586.74820143</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F1BE3F4-CA42-4591-9A5D-80D003BB473A</gtr:id><gtr:title>Intragenic enhancers act as alternative promoters.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac9f815f8954a372c5b5386ab75d02e0"><gtr:id>ac9f815f8954a372c5b5386ab75d02e0</gtr:id><gtr:otherNames>Kowalczyk MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>pm_14185_25_22264824</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28D553DD-FE75-4F65-A9F9-0C18CFC07912</gtr:id><gtr:title>MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/796bb4dc0bdb618cbf6ae9b953e99bc6"><gtr:id>796bb4dc0bdb618cbf6ae9b953e99bc6</gtr:id><gtr:otherNames>Benito JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5685130daf21a6.89235337</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C23F6748-D82F-45B6-B4F4-449E9BD036EC</gtr:id><gtr:title>MLL5 expression as a biomarker for DNA hypermethylation and sensitivity to epigenetic therapy.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a27ff98c559f42e5f2aab1c078749b0"><gtr:id>4a27ff98c559f42e5f2aab1c078749b0</gtr:id><gtr:otherNames>Milne TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>545a7e670ffb27.34243561</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>202593E2-80DD-4AB1-8B36-28654B5C3135</gtr:id><gtr:title>Metabolic gatekeeper function of B-lymphoid transcription factors.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b330aced857d541b8c7cdd6fea984dec"><gtr:id>b330aced857d541b8c7cdd6fea984dec</gtr:id><gtr:otherNames>Chan LN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5a941541721055.70324592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F52211D-87A1-4556-B304-E91B401B0617</gtr:id><gtr:title>LEDGF: a leukemia-specific target.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a27ff98c559f42e5f2aab1c078749b0"><gtr:id>4a27ff98c559f42e5f2aab1c078749b0</gtr:id><gtr:otherNames>Milne TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a941540a27e42.99020165</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7603ABD2-29D0-47DB-AD35-9E9D33543A82</gtr:id><gtr:title>Dangerous liaisons: cooperation between Pbx3, Meis1 and Hoxa9 in leukemia.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ba7325f8e3bedb487aab5a13d7795c3"><gtr:id>1ba7325f8e3bedb487aab5a13d7795c3</gtr:id><gtr:otherNames>Thorne RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>566f00d7408bd3.07742388</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8F5D496-A0D9-4BE4-BCF7-C6222E272C83</gtr:id><gtr:title>Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis.</gtr:title><gtr:parentPublicationTitle>Cancers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50749bb4cdf5b3cc58c8cedd13709504"><gtr:id>50749bb4cdf5b3cc58c8cedd13709504</gtr:id><gtr:otherNames>Ballabio E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2072-6694</gtr:issn><gtr:outcomeId>545a7ee4f1e072.26767924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D97E77F9-7DD6-4B4C-8917-267206752F00</gtr:id><gtr:title>Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97afc826f99792379d9a5ce7c48ea5cb"><gtr:id>97afc826f99792379d9a5ce7c48ea5cb</gtr:id><gtr:otherNames>Biswas D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_14185_25_21896721</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E94E1C8D-C302-4AD9-B3B0-49EB7FF33E1D</gtr:id><gtr:title>MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27&amp;nbsp;acetylation.</gtr:title><gtr:parentPublicationTitle>Experimental hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3884bf14da03fa4c535aae5731896efe"><gtr:id>3884bf14da03fa4c535aae5731896efe</gtr:id><gtr:otherNames>Godfrey L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0301-472X</gtr:issn><gtr:outcomeId>58946251ab1428.90539891</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D85E7D87-B5D5-443F-B4E6-3F2CD6E29215</gtr:id><gtr:title>Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50749bb4cdf5b3cc58c8cedd13709504"><gtr:id>50749bb4cdf5b3cc58c8cedd13709504</gtr:id><gtr:otherNames>Ballabio E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2372-3556</gtr:issn><gtr:outcomeId>5a94154194db88.37268242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BED87042-8CC3-4BB6-A089-C3D7A8E8F9F3</gtr:id><gtr:title>Ezh2 and Runx1 Mutations Collaborate to Initiate Lympho-Myeloid Leukemia in Early Thymic Progenitors.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ac49b0457a941477ada423553ad6694"><gtr:id>3ac49b0457a941477ada423553ad6694</gtr:id><gtr:otherNames>Booth CAG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>5a94154073cf87.30390365</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BB8C613-FACA-46F1-AD2C-3D5016A46F67</gtr:id><gtr:title>MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69d4678ef8eb0a47081688659e40a30e"><gtr:id>69d4678ef8eb0a47081688659e40a30e</gtr:id><gtr:otherNames>Stavropoulou V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>585d6c333807c8.94109726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67657AC1-ECE1-47A5-BE5F-A74BF57CB2DC</gtr:id><gtr:title>Hepcidin is regulated by promoter-associated histone acetylation and HDAC3.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/393f975ed0d279c1e271776d221d70b0"><gtr:id>393f975ed0d279c1e271776d221d70b0</gtr:id><gtr:otherNames>Pasricha SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a94154128e061.51585963</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2D5F333-8539-438D-B491-C40D1A942330</gtr:id><gtr:title>In situ functional dissection of RNA cis-regulatory elements by multiplex CRISPR-Cas9 genome engineering.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6851393d9a7ae503884c3ce687414648"><gtr:id>6851393d9a7ae503884c3ce687414648</gtr:id><gtr:otherNames>Wu Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a941541062e88.41641056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>706DA3F6-EA9F-4DD2-A9C1-6EB0FD48EFC6</gtr:id><gtr:title>The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77efd7b72a4510bf412217c95bb38d8f"><gtr:id>77efd7b72a4510bf412217c95bb38d8f</gtr:id><gtr:otherNames>Grey W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>5a941540c2aad3.18394794</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A9BB86E-30FF-44D0-A95F-9C3990BC78B0</gtr:id><gtr:title>Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4607c5ac340c37269cb822e1a7d9f86"><gtr:id>e4607c5ac340c37269cb822e1a7d9f86</gtr:id><gtr:otherNames>Geng H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>566f00d70c5a43.22565450</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B009B20A-53D7-4A44-98F6-6DC57C4D703A</gtr:id><gtr:title>RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/576a104cadcc89a4db3db0a9788dc2bc"><gtr:id>576a104cadcc89a4db3db0a9788dc2bc</gtr:id><gtr:otherNames>Wilkinson AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_14185_25_23352661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E5BE719-EA68-4314-9157-3DE282ADFA6B</gtr:id><gtr:title>Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c4b407709e22ffb9c7c74f5c532ba01"><gtr:id>0c4b407709e22ffb9c7c74f5c532ba01</gtr:id><gtr:otherNames>Ruthenburg AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>pm_14185_25_21596426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FBDF608-202A-49DA-8207-694B65B1E48C</gtr:id><gtr:title>Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfe761fa5778c23cae6bec0bce9029bc"><gtr:id>dfe761fa5778c23cae6bec0bce9029bc</gtr:id><gtr:otherNames>Lin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>585d33b47e89b9.53287455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0D3DFEF-397E-4247-8191-AC25AB5EDE53</gtr:id><gtr:title>Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50c5dc763bf7c99920e5973994d1ff44"><gtr:id>50c5dc763bf7c99920e5973994d1ff44</gtr:id><gtr:otherNames>Akalin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>pm_14185_25_22737091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49E6DE7A-E680-403A-921C-B992DFDC01D5</gtr:id><gtr:title>Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.</gtr:title><gtr:parentPublicationTitle>Cancer discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4607c5ac340c37269cb822e1a7d9f86"><gtr:id>e4607c5ac340c37269cb822e1a7d9f86</gtr:id><gtr:otherNames>Geng H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2159-8274</gtr:issn><gtr:outcomeId>pm_14185_25_23107779</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12009/6</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>